A machine-learned predictor of colonic polyps based on urinary metabolomics

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Eisner, Roman ^a   Greiner, Russell ^a   Tso, Victor ^a   Wang, Haili ^b   Fedorak, Richard N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

KETONE BODY; NICOTINAMIDE; NICOTINIC ACID; TRIGONELLINE; TYROSINE;

ADULT; ARTICLE; CANCER RISK; CANCER SCREENING; COLON ADENOMA; COLON POLYP; COLON POLYPOSIS; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FAMILY HISTORY; FECES ANALYSIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GOLD STANDARD; HUMAN; LEARNING ALGORITHM; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; OCCULT BLOOD TEST; PREDICTIVE VALUE; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; URINALYSIS; AGED; ARTIFICIAL INTELLIGENCE; CLINICAL TRIAL; COLON TUMOR; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PROGNOSIS; URINE;

ADULT; AGED; ARTIFICIAL INTELLIGENCE; COLONIC NEOPLASMS; COLONIC POLYPS; COLONOSCOPY; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOMICS; MIDDLE AGED; PROGNOSIS;

EID: 84888610357     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/303982     Document Type: Article

References (47)

1. International Agency for Research on Cancer, World Health Organization, Estimated cancer Incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide. GLOBOCAN 2008 2008 Lyon, France International Agency for Research on Cancer
2. Parkin D. M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 2005 55 2 74 108 2-s2.0-14944385553 (Pubitemid 40372904)
3. Colon and rectal cancer. National Cancer Institute http://www.cancer.gov/ cancertopics/types/colon-and-rectal
4. Canadian Cancer Society's Steering Committee on Cancer Statistics, Canadian Cancer Statistics 2011 Toronto, Canada
5. Leddin D. J., Enns R., Hilsden R., Plourde V., Rabeneck L., Sadowski D. C., Singh H., Canadian Association of Gastroenterology position statement on screening individuals at average risk for developing colorectal cancer: 2010. Canadian Journal of Gastroenterology 2010 24 12 705 714 2-s2.0-79953015202
6. Taylor D. P., Cannon-Albright L. A., Sweeney C., Williams M. S., Haug P. J., Mitchell J. A., Burt R. W., Comparison of compliance for colorectal cancer screening and surveillance by colonoscopy based on risk. Genetics in Medicine 2011 13 8 737 743 2-s2.0-80051802495 10.1097/GIM.0b013e3182180c71
7. Wong C. K. W., Fedorak R. N., Prosser C. I., Stewart M. E., van Zanten S. V., Sadowski D. C., The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. International Journal of Colorectal Disease 2012 27 12 1657 1664 10.1007/s00384-012-1518-3
8. Allison J. E., Tekawa I. S., Ransom L. J., Adrain A. L., A comparison of fecal occult-blood tests for colorectal-cancer screening. The New England Journal of Medicine 1996 334 3 155 159 2-s2.0-0030049351 10.1056/ NEJM199601183340304 (Pubitemid 26017953)
9. Imperiale T. F., Ransohoff D. F., Itzkowitz S. H., Turnbull B. A., Ross M. E., Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. The New England Journal of Medicine 2004 351 26 2704 2714 2-s2.0-10844281210 10.1056/NEJMoa033403 (Pubitemid 39665324)
10. Whitlock E. P., Lin J. S., Liles E., Beil T. L., Fu R., Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Annals of Internal Medicine 2008 149 9 638 658 2-s2.0-55749084228
11. Maroun J., Ng E., Berthelot J.-M., le Petit C., Dahrouge S., Flanagan W. M., Walker H., Evans W. K., Lifetime costs of colon and rectal cancer management in Canada. Chronic Diseases in Canada 2003 24 4 91 101 2-s2.0-0742266688 (Pubitemid 38155547)
12. Wishart D. S., Jewison T., Guo A. C., HMDB 3.0-the human metabolome database in 2013. Nucleic Acids Research 2013 41 D801 D807 1093/nar/gks1065
13. 1H-NMR metabolomics data. Analytical Chemistry 2006 78 13 4430 4442 2-s2.0-33745700438 10.1021/ac060209g
14. Wishart D. S., Quantitative metabolomics using NMR. TrAC-Trends in Analytical Chemistry 2008 27 3 228 237 2-s2.0-41049096359 10.1016/j.trac.2007. 12.001
15. 1H-NMR profiles of urinary metabolites. Metabolomics 2011 7 1 25 34 2-s2.0-79951727039 10.1007/s11306-010-0232-9
16. Stretch C., Eastman T., Mandal R., Eisner R., Wishart D. S., Mourtzakis M., Prado C. M. M., Damaraju S., Ball R. O., Greiner R., Baracos V. E., Prediction of skeletal muscle and fat mass in patients with advanced cancer using a metabolomic approach. Journal of Nutrition 2012 142 1 14 21 2-s2.0-84855564151 10.3945/jn.111.147751
17. Xia J., Psychogios N., Young N., Wishart D. S., MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic Acids Research 2009 37 2 W652 W660 2-s2.0-67849106535 10.1093/nar/gkp356
18. 1H nuclear magnetic resonance spectra of human urine from normal and pathological states. Analytical Biochemistry 1994 220 2 284 296 2-s2.0-0028015622 10.1006/abio.1994.1339 (Pubitemid 24261170)
19. 1H-NMR metabonomics. Analytical Chemistry 2006 78 13 4281 4290 2-s2.0-33745728718 10.1021/ac051632c
20. Bollard M. E., Stanley E. G., Lindon J. C., Nicholson J. K., Holmes E., NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR in Biomedicine 2005 18 3 143 162 2-s2.0-19144371287 10.1002/nbm.935 (Pubitemid 40716122)
21. Craig A., Cloarec O., Holmes E., Nicholson J. K., Lindon J. C., Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Analytical Chemistry 2006 78 7 2262 2267 2-s2.0-33645663178 10.1021/ac0519312
22. Spratlin J. L., Serkova N. J., Eckhardt S. G., Clinical applications of metabolomics in oncology: a review. Clinical Cancer Research 2009 15 2 431 440 2-s2.0-59449097019 10.1158/1078-0432.CCR-08-1059
23. Madsen R., Lundstedt T., Trygg J., Chemometrics in metabolomics-a review in human disease diagnosis. Analytica Chimica Acta 2010 659 1-2 23 33 2-s2.0-72549095180 10.1016/j.aca.2009.11.042
24. Vapnik V., The Nature of Statistical Learning Theory 1995 New York, NY, USA Springer
25. Frank E., Hall M., Holmes G., Maimon O., Rokach L., Weka-A machine learning workbench for data mining. Data Mining and Knowledge Discovery Handbook 2010 2nd Springer 1269 1277 10.1007/978-0-387-09823-4-66
26. Tibshirani R., Regression shrinkage and selection via the Lasso. Journal of the Royal Statistical Society B 1996 58 267 288
27. Hastie T., Tibshirani R., Friedman J., The Elements of Statistical Learning 2001 New York, NY, USA Springer
28. Provost F., Fawcett T., Analysis and Visualization of Classifier Performance: Comparison under Imprecise Class and Cost Distributions 1997 AAAI Press
29. Scott M. J. J., Niranjan M., Prager R. W., Realisable classifiers: improving operating performance on variable cost problems. Proceedings of 9th British Machine Vision Conferenc 1998 Southampton, UK University of Southampton 304 315
30. Russell S. J., Norvig P., Artificial Intelligence: A Modern Approach 2002 Upper Saddle River, NJ, USA Prentice Hall
31. Ding C., Peng H., Minimum redundancy feature selection from microarray gene expression data. Journal of Bioinformatics and Computational Biology 2005 3 2 185 205 2-s2.0-17644384367 10.1142/S0219720005001004 (Pubitemid 40561382)
32. Huang T., Wan S., Xu Z., Zheng Y., Feng K.-Y., Li H.-P., Kong X., Cai Y.-D., Analysis and prediction of translation rate based on sequence and functional features of the mRNA. PLoS ONE 2011 6 1 2-s2.0-79251548286 10.1371/journal.pone.0016036 e16036
33. Sun L., Yu Y., Huang T., Associations between ionomic profile and metabolic abnormalities in human population. PLoS ONE 2012 7 6 e38845 10.1371/journal.pone.0038845
34. Guyon I., Weston J., Barnhill S., Vapnik V., Gene selection for cancer classification using support vector machines. Machine Learning 2002 46 1-3 389 422 2-s2.0-0036161259 10.1023/A:1012487302797 (Pubitemid 34129977)
35. Pesarin F., Multivariate Permutation Tests: With Applications in Biostatistics 2001 Chichester, UK John Wiley & Sons
36. Qiu Y., Cai G., Su M., Chen T., Zheng X., Xu Y., Ni Y., Zhao A., Xu L. X., Cai S., Jia W., Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. Journal of Proteome Research 2009 8 10 4844 4850 2-s2.0-70350028279 10.1021/pr9004162
37. Cheng Y., Xie G., Chen T., Qiu Y., Zou X., Zheng M., Tan B., Feng B., Dong T., He P., Zhao L., Zhao A., Xu L. X., Zhang Y., Jia W., Distinct urinary metabolic profile of human colorectal cancer. Journal of Proteome Research 2012 11 2 1354 1363 2-s2.0-84856667021 10.1021/pr201001a
38. Wang W., Feng B., Li X., Yin P., Gao P., Zhao X., Lu X., Zheng M., Xu G., Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry. Molecular BioSystems 2010 6 10 1947 1955 2-s2.0-77956518768 10.1039/c004994h
39. Wang H., Schiller D. E., Tso V., Slupsky C., Wong C. K., Fedorak R. N., A novel highly sensitive test for detecting colon cancer using spot urine metabolomics. Gastroenterology 140 5, supplement 1 S40 10.1016/S0016-5085(11) 60160-1
40. Qiu Y., Cai G., Su M., Chen T., Liu Y., Xu Y., Ni Y., Zhao A., Cai S., Xu L. X., Jia W., Urinary metabonomic study on colorectal cancer. Journal of Proteome Research 2010 9 3 1627 1634 2-s2.0-77949822339 10.1021/pr901081y
41. Nishiumi S., Kobayashi T., Ikeda A., A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS ONE 2012 7 7 e40459 10.1371/journal.pone.0040459
42. Mal M., Koh P. K., Cheah P. Y., Chan E. C. Y., Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry. Analytical and Bioanalytical Chemistry 2012 403 2 483 493 2-s2.0-84857389022 10.1007/s00216-012-5870-5
43. Ma Y., Zhang P., Wang F., Liu W., Yang J., Qin H., An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer. Annals of Surgery 2012 255 4 720 730 2-s2.0-84858706745 10.1097/SLA.0b013e31824a9a8b
44. Wang H., Tso V. K., Slupsky C. M., Fedorak R. N., Metabolomics and detection of colorectal cancer in humans: a systematic review. Future Oncology 2010 6 9 1395 1406 2-s2.0-77957964117 10.2217/fon.10.107
45. Farshidfar F., Weljie A. M., Kopciuk K., Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Medicine 2012 4, article 42 10.1186/gm341
46. Miyagi Y., Higashiyama M., Gochi A., Akaike M., Ishikawa T., Miura T., Saruki N., Bando E., Kimura H., Imamura F., Moriyama M., Ikeda I., Chiba A., Oshita F., Imaizumi A., Yamamoto H., Miyano H., Horimoto K., Tochikubo O., Mitsushima T., Yamakado M., Okamoto N., Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS ONE 2011 6 9 2-s2.0-80052526020 10.1371/journal.pone.0024143 e24143
47. Arlt A., Sebens S., Krebs S., Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene 2012 10.1038/onc.2012.493